Circulating Cell‐Free RNA Reflects Immune‐Associated and Airway Remodeling Signatures in Equine Asthma
Journal of Immunology Research · 2026
DOI: 10.1155/jimr/5310284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology Research, 2026. Verfasst von Birong Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Uppsala University, Uppsala, Sweden, uu.se. Hauptthemen laut MEDLINE: Asthma, Airway Remodeling, Cell-Free Nucleic Acids, Horse Diseases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish-Norwegian Foundation for Equine Research, FORMAS, Uppsala Universitet.
Abstract (Originalsprache)
Circulating cell‐free RNA (cfRNA) has emerged as a promising minimally invasive biomarker capable of capturing transcripts originating from multiple tissues and cell types, but its utility in chronic inflammatory airway diseases remains poorly understood. Equine asthma (EA), a naturally occurring respiratory disease that shares key clinical and immunopathological features with human asthma, provides a valuable comparative model for evaluating plasma cfRNA in this context. We performed transcriptomic profiling of plasma cfRNA from horses with EA and healthy controls and compared these findings with partially matched bronchoalveolar lavage (BAL) and whole‐blood (WB) transcriptomes. Differential abundance analysis of plasma cfRNA identified increased abundance of the epithelial alarmin IL33 , together with signatures associated with tissue remodeling, cellular stress responses, and immune alterations. Notably, cfRNA from EA horses exhibited reduced B‐cell–associated and increased T‐cell–associated transcript signatures, a pattern independently supported by differential abundance, co‐expression network, and deconvolution analyses. In contrast, similar immune‐associated signatures were not evident in the BAL and WB transcriptomes analyzed in this study. Cross‐compartment comparisons further demonstrated that plasma cfRNA captured a molecular profile largely distinct from those identified in BAL and WB, while sharing only a small set of differentially abundant transcripts across compartments. Collectively, these findings indicate that plasma cfRNA captures molecular patterns associated with EA that differ from those observed in conventional transcriptomic sampling compartments. These results support the potential utility of plasma cfRNA as a minimally invasive source of biomarkers for characterizing airway disease‐associated molecular and immune alterations in both veterinary and comparative asthma research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Uppsala University, Uppsala, Sweden, uu.se.
- Science for Life Laboratory, Uppsala, Sweden, scilifelab.se.
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden, slu.se.
- Department of Veterinary Clinical Sciences, University of Copenhagen, Copenhagen, Denmark, ku.dk.
ORCID-Profile: Birong Zhang, Hanna Agdour, Miia Riihimäki, Sanni Hansen, Amanda Raine
Förderung
- Swedish-Norwegian Foundation for Equine Research
- FORMAS
- Uppsala Universitet
Zitieren
APA
Zhang, B., Agdour, H., Riihimäki, M., Hansen, S., & Raine, A. (2026). Circulating Cell‐Free RNA Reflects Immune‐Associated and Airway Remodeling Signatures in Equine Asthma. Journal of Immunology Research. https://doi.org/10.1155/jimr/5310284
Vancouver
Zhang B, Agdour H, Riihimäki M, Hansen S, Raine A. Circulating Cell‐Free RNA Reflects Immune‐Associated and Airway Remodeling Signatures in Equine Asthma. Journal of Immunology Research. 2026. doi:10.1155/jimr/5310284
BibTeX
@article{Zhang2026,
author = {Zhang, Birong and Agdour, Hanna and Riihimäki, Miia and Hansen, Sanni and Raine, Amanda},
title = {Circulating Cell‐Free RNA Reflects Immune‐Associated and Airway Remodeling Signatures in Equine Asthma},
journal = {Journal of Immunology Research},
year = {2026},
doi = {10.1155/jimr/5310284}
}
EUVIMED